In-105

Biocon, India's top listed biotech firm, on Friday announced an agreement with Bristol-Myers Squibb for its oral insulin drug IN-105. The deal could potentially earn Biocon hundreds of millions of dollars in royalties. Bristol-Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide license to the program, Biocon said...

Biocon, India's top listed biotech firm, on Friday announced an agreement with Bristol-Myers Squibb for its oral insulin drug IN-105. The deal could potentially earn Biocon hundreds of millions of dollars in royalties. Bristol-Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide license to the program, Biocon said...